RLCK176 Antibody

What is RLCK176 and why is it important to study?

RLCK176 is a receptor-like cytoplasmic kinase that functions as a positive regulator of rice immunity. It belongs to the family of RLCKs that transmit immune signals from pattern recognition receptors (PRRs) to downstream components. RLCK176 has been shown to interact with the monocot-specific receptor-like kinase SDS2, which plays a role in programmed cell death (PCD) and immunity regulation in rice . Unlike some other RLCKs such as RLCK118, RLCK176 does not show detectable kinase activity in in vitro assays . The importance of studying RLCK176 lies in understanding plant immune signaling pathways, which can lead to the development of crops with enhanced disease resistance.

To study RLCK176, researchers typically use a combination of genetic approaches (such as T-DNA insertion mutants), protein-protein interaction assays, and phenotypic analyses of mutant plants challenged with pathogens. The osrlck176 mutant plants generate less reactive oxygen species (ROS) upon chitin and flg22 treatments and show enhanced susceptibility to pathogens like Magnaporthe oryzae .

How does RLCK176 function in plant immunity signaling pathways?

RLCK176 functions downstream of pattern recognition receptors in plant immunity signaling pathways. When plants detect pathogen-associated molecular patterns (PAMPs) like chitin and peptidoglycan (PGN), PRRs at the plasma membrane initiate immune responses. RLCK176 works downstream of these sensing mechanisms and has been shown to be involved in brassinosteroid (BR) signaling as well .

Unlike RLCK118, which interacts with and phosphorylates the NADPH oxidase OsRbohB to induce ROS burst during pathogen infection, RLCK176 appears to have a different role in immune responses. It interacts with SDS2, a monocot-specific receptor-like kinase that positively regulates programmed cell death and immunity by forming complexes with the E3 ligase SPL11 and RLCK118/176 . Methodologically, the function of RLCK176 in immunity signaling can be studied using genetic approaches (knockout mutants), biochemical assays for protein-protein interactions, and phenotypic analyses of mutant plants under pathogen challenge.

What are the known protein interactions of RLCK176?

Current research indicates that RLCK176 interacts with several key proteins in the plant immunity pathway:

• SDS2 (Stress-induced Death Suppressor 2): RLCK176 interacts with SDS2 in both in vivo and in vitro assays. This interaction was confirmed using pull-down assays that demonstrated direct physical interaction between the proteins .

• SPL11 (Spotted Leaf 11): While direct interaction with SPL11 has not been conclusively demonstrated, genetic evidence suggests a functional relationship, as SDS2 forms complexes with both SPL11 and RLCK176 .

• Other potential partners: Given its role in immunity signaling, RLCK176 may interact with components of the PAMP-triggered immunity (PTI) pathway, including PRRs or their co-receptors, though these interactions require further investigation.

To study these interactions, researchers typically employ yeast two-hybrid assays, co-immunoprecipitation experiments, bimolecular fluorescence complementation, and pull-down assays with recombinant proteins.

What strategies should be used to develop antibodies against RLCK176?

Developing antibodies against RLCK176 requires careful consideration of several factors:

• Antigen preparation: For producing antibodies against RLCK176, researchers should consider expressing the recombinant protein in eukaryotic expression systems (like HEK293T cells) to ensure proper post-translational modifications. This approach has proven successful for generating antibodies against heavily glycosylated proteins .

• Immunization protocols: A typical immunization protocol would involve:

  • Initial immunization with complete Freund's adjuvant

  • Booster immunizations with incomplete Freund's adjuvant at 2-week intervals

  • Monitoring antiserum titers using ELISA against the recombinant RLCK176

  • Sacrificing mice when titers reach satisfactory levels (typically 1:6.4×10⁴)

• Hybridoma selection: After fusion of splenocytes with myeloma cells (e.g., Sp2/0-Ag14), hybridomas should be selected and screened for antibody production using both ELISA against recombinant RLCK176 and functional assays with cells expressing native RLCK176.

The development process typically takes approximately 2 months from initial immunization to obtaining stable hybridoma clones, assuming efficient screening methods are employed .

How can the specificity of RLCK176 antibodies be validated?

Validating the specificity of RLCK176 antibodies requires multiple complementary approaches:

• Western blot analysis:

  • Using recombinant RLCK176 and plant cell lysates from wild-type and rlck176 knockout plants

  • Testing cross-reactivity with closely related RLCKs (particularly RLCK118)

  • Comparing band patterns between wild-type and mutant tissues

• Immunoprecipitation:

  • Performing immunoprecipitation followed by mass spectrometry to confirm capture of authentic RLCK176

  • Analyzing co-precipitated proteins to validate known interactions (e.g., with SDS2)

• Immunofluorescence:

  • Comparing staining patterns in wild-type versus rlck176 knockout plants

  • Co-localization studies with known interaction partners

• Surface Plasmon Resonance (SPR):

  • Determining binding kinetics (K_D) to recombinant RLCK176

  • Comparing binding to related RLCK proteins to assess cross-reactivity

What are the optimal epitope selection strategies for RLCK176 antibody development?

When selecting epitopes for RLCK176 antibody development, researchers should consider:

• Domain-specific targeting:

  • The kinase domain, though conserved, may contain RLCK176-specific regions

  • N-terminal regions often show greater sequence divergence among RLCKs

  • C-terminal sequences that may be involved in protein-protein interactions

• Bioinformatic analysis:

  • Hydrophilicity plots to identify surface-exposed regions

  • Sequence alignment with related RLCKs to identify unique regions

  • Secondary structure prediction to avoid targeting structured domains that may be inaccessible

• Functional considerations:

  • Targeting regions involved in SDS2 interaction if studying this specific interaction

  • Avoiding epitopes that might block functional sites if planning to use antibodies in functional assays

  • Considering phosphorylation sites if developing phospho-specific antibodies

For monoclonal antibody development, employing the full-length recombinant protein as an immunogen (rather than peptides) often yields antibodies recognizing diverse epitopes, some of which may recognize the native conformation of RLCK176 at the plasma membrane .

How can RLCK176 antibodies be used to study protein-protein interactions in plant immunity?

RLCK176 antibodies provide valuable tools for studying protein-protein interactions in plant immunity pathways using several approaches:

• Co-immunoprecipitation (Co-IP):

  • Using RLCK176 antibodies to precipitate protein complexes from plant extracts

  • Analyzing co-precipitated proteins by mass spectrometry or western blot

  • Confirming known interactions (with SDS2) and discovering novel interaction partners

• Proximity-dependent labeling:

  • Coupling RLCK176 antibodies with enzymes like BioID or APEX2

  • Identifying proteins in close proximity to RLCK176 in living cells

  • Mapping the spatial organization of RLCK176-containing complexes

• In situ detection of protein complexes:

  • Proximity ligation assays (PLA) to visualize protein interactions in plant cells

  • Co-localization studies using fluorescently labeled antibodies against RLCK176 and potential partners

• Dynamic interaction studies:

  • Using RLCK176 antibodies to track changes in protein interactions during immune responses

  • Temporal analysis of complex formation following PAMP treatment

These approaches can reveal how RLCK176 participates in signaling complexes with SDS2 and potentially other components of the rice immunity pathway, providing insights into the molecular mechanisms of plant defense responses.

What methodological approaches can resolve contradictory data regarding RLCK176 function?

Resolving contradictory data regarding RLCK176 function requires systematic experimental approaches:

• Genetic redundancy analysis:

  • Generate double/triple mutants of closely related RLCKs (e.g., rlck176/rlck118)

  • Compare phenotypes of single and higher-order mutants

  • Perform complementation studies with wild-type and mutant versions of RLCK176

• Tissue-specific and conditional studies:

  • Use tissue-specific or inducible expression systems

  • Analyze RLCK176 function in different cell types and developmental stages

  • Employ different pathogen challenge models to assess context-dependent functions

• Biochemical activity reconciliation:

  • Investigate whether RLCK176, despite lacking detectable in vitro kinase activity , might:

    • Require specific activation conditions

    • Function as a pseudokinase or scaffold protein

    • Exhibit alternative enzymatic activities

• Systems biology approaches:

  • Transcriptome analysis of rlck176 mutants under different conditions

  • Phosphoproteomics to identify potential substrates or signaling events

  • Network modeling to place RLCK176 in broader signaling contexts

By employing these complementary approaches, researchers can resolve seemingly contradictory data and develop a more comprehensive understanding of RLCK176's role in plant immunity.

How can RLCK176 antibodies facilitate the study of RLCK176 phosphorylation state and its impact on signaling?

RLCK176 antibodies can be powerful tools for studying phosphorylation states and their impact on signaling:

• Phospho-specific antibodies:

  • Develop antibodies that specifically recognize phosphorylated forms of RLCK176

  • Map phosphorylation sites using mass spectrometry

  • Generate site-specific phospho-antibodies for key regulatory sites

• Temporal dynamics of phosphorylation:

  • Track RLCK176 phosphorylation status during immune responses

  • Correlate phosphorylation with complex formation and downstream signaling

  • Identify kinases that phosphorylate RLCK176 using in vitro kinase assays

• Functional impact assessment:

  • Combine phospho-specific antibodies with functional assays

  • Correlate phosphorylation status with ROS production and defense gene expression

  • Analyze the impact of phosphorylation-deficient RLCK176 mutants on plant immunity

• Structural studies:

  • Use antibodies to purify RLCK176 for structural analysis

  • Compare structures of phosphorylated and non-phosphorylated forms

  • Investigate how phosphorylation affects interaction with partners like SDS2

These approaches can reveal how RLCK176 phosphorylation status regulates its activity and interactions, providing mechanistic insights into its role in immune signaling.

What are the optimal experimental conditions for using RLCK176 antibodies in different applications?

The optimal conditions for using RLCK176 antibodies vary by application:

• Western Blotting:

  • Sample preparation: Cell lysis in buffer containing phosphatase inhibitors to preserve phosphorylation status

  • Blocking: 5% skim milk in PBS or TBST (though BSA may be preferred for phospho-detection)

  • Primary antibody dilution: Typically 1:1000 to 1:5000 depending on antibody quality

  • Incubation: Overnight at 4°C for maximum sensitivity

  • Detection: HRP-conjugated secondary antibodies with ECL detection systems

• Immunofluorescence:

  • Fixation: 4% paraformaldehyde for 10-15 minutes

  • Permeabilization: 0.1% Triton X-100 in PBS for membrane proteins

  • Blocking: 3-5% BSA in PBS

  • Antibody concentration: Typically 25 μg/mL (similar to protocols used for other membrane proteins)

  • Washing: Multiple PBS washes to reduce background

  • Co-staining with DAPI for nuclei visualization

• Immunoprecipitation:

  • Antibody immobilization on Protein G beads

  • Pre-clearing lysates to reduce non-specific binding

  • Antibody-to-protein ratio optimization (typically 2-5 μg antibody per mg of total protein)

  • Implementing stringent washing steps to reduce background

What troubleshooting approaches should be used when RLCK176 antibodies give inconsistent results?

When facing inconsistent results with RLCK176 antibodies, consider these troubleshooting approaches:

• Antibody validation issues:

  • Re-validate antibody specificity using positive and negative controls

  • Check antibody performance batch-to-batch with standard samples

  • Consider epitope accessibility in different sample preparation methods

• Sample preparation problems:

  • Ensure consistent protein extraction methods

  • Check for proteolytic degradation by adding protease inhibitors

  • For phosphorylation studies, verify phosphatase inhibitor effectiveness

  • Consider native versus denaturing conditions if studying conformational epitopes

• Technical variables:

  • Standardize incubation times and temperatures

  • Optimize antibody concentration for each application

  • Validate secondary antibody specificity

  • Check for interfering substances in buffers

• Statistical approaches:

  • Increase biological and technical replicates

  • Implement normalization procedures

  • Use appropriate statistical tests to determine significance of results

How can RLCK176 antibodies be modified or conjugated for specialized research applications?

RLCK176 antibodies can be modified or conjugated for specialized applications using several approaches:

• Fluorescent conjugation:

  • Direct labeling with fluorophores like Alexa Fluor dyes for immunofluorescence and flow cytometry

  • Sequential labeling strategies for multi-parameter imaging

  • Use of Protein Labeling Kits for consistent dye-to-protein ratios

• Enzymatic conjugation:

  • HRP conjugation for western blotting and immunohistochemistry

  • Alkaline phosphatase conjugation for applications requiring alternative detection methods

  • Biotin conjugation for streptavidin-based amplification systems

• Affinity tag addition:

  • Biotinylation for streptavidin-based purification or detection

  • Adding His-tags for oriented immobilization on metal affinity surfaces

  • Fc-specific chemical modification for oriented immobilization

• Fragmentation:

  • F(ab')₂ or Fab fragment generation to eliminate Fc-mediated effects

  • Single-chain variable fragments (scFv) for improved tissue penetration

  • Camelid single-domain antibodies for specialized applications

The choice of modification depends on the specific research application. For example, when studying membrane-localized RLCK176 in living cells, directly conjugated fluorescent antibodies may be preferred. For sensitive detection in fixed samples, enzyme conjugates with signal amplification might be more appropriate.

How can RLCK176 antibodies be integrated into high-throughput screening platforms for plant immunity modulators?

RLCK176 antibodies can be integrated into high-throughput screening platforms through several innovative approaches:

• Antibody-based biosensors:

  • Developing FRET-based biosensors using RLCK176 antibodies and fluorescently tagged RLCK176

  • Creating split-GFP complementation systems for detecting RLCK176 interactions

  • Utilizing label-free detection platforms like Surface Plasmon Resonance (SPR)

• Cell-based screening assays:

  • Establishing reporter systems where RLCK176 activity triggers measurable outputs

  • Creating high-content imaging platforms using fluorescently labeled RLCK176 antibodies

  • Developing phospho-specific assays to detect RLCK176 activation

• Microarray and multiplex technologies:

  • Immobilizing RLCK176 antibodies on protein microarrays to detect interactions

  • Employing antibody arrays to monitor RLCK176 expression across multiple conditions

  • Developing multiplex bead-based assays for simultaneous detection of RLCK176 and interacting partners

• Automated screening platforms:

  • Integrating RLCK176 antibody-based detection into robotic screening systems

  • Coupling with automated image analysis to quantify complex phenotypes

  • Implementing machine learning algorithms to identify subtle phenotypic changes

These platforms can accelerate the discovery of compounds that modulate plant immunity by affecting RLCK176 function or its interactions with partners like SDS2.

What are the methodological considerations for developing RLCK176 antibodies that can distinguish between phosphorylated and non-phosphorylated forms?

Developing phospho-specific RLCK176 antibodies requires specialized approaches:

• Phosphopeptide immunization strategy:

  • Identifying key phosphorylation sites using mass spectrometry

  • Synthesizing phosphopeptides corresponding to these sites

  • Conjugating phosphopeptides to carrier proteins for immunization

  • Including non-phosphorylated peptides in screening to eliminate antibodies recognizing both forms

• Phospho-specific screening methods:

  • Developing parallel ELISA screens with phosphorylated and non-phosphorylated antigens

  • Utilizing dot blot arrays with phosphatase-treated and untreated samples

  • Employing western blots of samples from cells treated with kinase activators and inhibitors

• Validation requirements:

  • Confirming specificity using phosphatase-treated samples

  • Validating with phosphorylation-site mutants (Ser/Thr/Tyr to Ala)

  • Testing across different experimental conditions that alter phosphorylation status

• Technical optimization:

  • Determining optimal blocking agents (BSA typically preferred over milk for phospho-detection)

  • Optimizing buffer compositions to maintain phospho-epitope integrity

  • Establishing appropriate negative controls (phosphatase-treated samples, phospho-null mutants)

The development of phospho-specific antibodies would enable researchers to track RLCK176 activation status during immune responses and correlate it with downstream signaling events.

How can computational approaches enhance the design and application of RLCK176 antibodies?

Computational approaches can significantly enhance RLCK176 antibody design and application:

• Epitope prediction and optimization:

  • Using machine learning algorithms to predict immunogenic epitopes

  • Applying molecular dynamics simulations to assess epitope accessibility

  • Employing structural modeling to optimize antibody-antigen interactions

  • Designing antibodies that target RLCK176-specific regions to minimize cross-reactivity

• Antibody engineering:

  • In silico affinity maturation to enhance binding properties

  • Computational design of bispecific antibodies targeting RLCK176 and interacting partners

  • Virtual screening of antibody libraries for improved specificity and affinity

  • Structure-based optimization of antibody stability and solubility

• Data integration and analysis:

  • Developing algorithms to analyze antibody-based imaging data

  • Creating databases of antibody binding profiles across experimental conditions

  • Implementing network analysis tools to contextualize RLCK176 interactions

  • Utilizing machine learning for pattern recognition in large-scale antibody screening data

• Experimental design optimization:

  • Power analysis to determine optimal sample sizes for experiments

  • Experimental design algorithms to maximize information gain while minimizing resources

  • Statistical models to account for technical and biological variability

These computational approaches can accelerate the development of high-quality RLCK176 antibodies and enhance their application in plant immunity research.